Orphan drug reimbursement should take more than just cost into account, says Eurordis
This article was originally published in Scrip
The European rare disease association Eurordis has called on drug reimbursement authorities to bear in mind that while orphan medicines may be expensive, there are relatively few of them and they will be taken by very small numbers of patients.
You may also be interested in...
The EU has published an action plan that is intended to upgrade the bloc’s intellectual property framework while ensuring that goods such as medicines and vaccines are made as widely available as possible. The initiative is part of wide-ranging plans to support member states’ recovery from the pandemic crisis and help ensure the EU’s resilience to future health threats.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.